Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Ophthalmologists

Articles with lock require a subscription to GLG News | Request a free trial
July 11, 2007
AMO's Acquisition of Baush & Lomb: A New Force in Ophthalmology?
Analysis of: AMO outbids private equity firm for Bausch & Lomb | www.osnsupersite.com
Author: GLG Expert Contributor
AMO (EYE) recently outbid a private equity firm to acquire Bausch & Lomb (BOL).  It has the potential to add to AMO's market share and establish it as the force in Ophthalmology.
Mark PackerJuly 10, 2007
AMO Seeks B & L
Analysis of: AMO outbids private equity firm for Bausch & Lomb | www.osnsupersite.com
Author: Mark Packer, Clinical Associate Professor of Ophthalmology, OREGON HEALTH & SCIENCE UNIVERSITY - CC
Currently the ophthalmic device market is organized into an oligopoly including Alcon, AMO and Bausch.  AMO has shown fairly dramatic growth with its acquisition of VISX, Intralase and Wavefront Sciences.  However, AMO's potential acquisition of Bausch is on a grander scale.  There are...
July 10, 2007
AMO makes Bid for Bausch and Lomb
Analysis of: AMO outbids private equity firm for Bausch & Lomb | www.osnsupersite.com
Author: GLG Expert Contributor
In this news release presented today, this leading ophthalmic journal reports that AMO has presented the highest bid for the purchase of Bausch and Lomb.  
July 2, 2007
COST EFFECTIVENESS OF AVASTIN MAY BE HUGE ….VERDICT STILL OUT ON ITS SAFETY AND EFFECTIVENESS FOR MACULAR DEGENERATION
Analysis of: Costs of Visual Benefits in Treating Age-Related Macular Degeneration | www.ophsource.org
Author: GLG Expert Contributor
Dr Smiddy reviewed age-related macular degeneration studies to evaluate the cost for the visual benefit of various treatment approaches, and then compared them with the costs for treating other retinal conditions. This study founds costs for treating wet macular degeneation could be as high as $9000...
July 2, 2007
PDT MAY CONTINUE TO SERVE A ROLE IN THE TREATMENT OF WET MACULAR DEGENERATION
Analysis of: Verteporfin and Intravitreal Bevacizumab Combination Treatment | www.ophsource.org
Author: GLG Expert Contributor
In a study of patients with choroidal neovascularization due to age-related macular degeneration, Lazic and Gabric demonstrated that improvements in vision and reduction of central macular thickness after one month and their maintenance over three months are more significant after verteporfin photodynamic...
July 2, 2007
SMOKING INCREASES RISK OF BLINDNESS DUE TO MACULAR DEGENERATION
Analysis of: European Eye Study Links Cigarette Smoking to Age-Related Macular Degeneration | www.ophsource.org
Author: GLG Expert Contributor
The European Eye Study (EUREYE) investigated 4,750 randomly sampled people over age 65 and examined the association between cigarette smoking and age-related macular degeneration and concluded that there is a postive correlation to smoking and blindness from macular degeneration.
July 2, 2007
AMO will Push Hard to Increase INTRALASE Penetration in the LASIK Market in 2008 and Beyond
Analysis of: Femtosecond Laser for Penetrating Keratoplasty | www.ajo.com
Author: GLG Expert Contributor
In this latest study with the Intralase femtosecond laser, we see its versatility in being able to produce very efficient and safe corneal cuts for corneal transplant surgery. In addition to producing significant benefits for patients that undergo LASIK, this laser has thereaputic benefits that will...
July 2, 2007
DELIVERY SYSTEM OF NEW MACULAR DEGENERATION DRUGS MAY BECOME VERY IMPORTANT
Analysis of: Intravitreous Dexamethasone Drug Delivery System in Patients With Persistent Macular Edema | archopht.ama-assn.org
Author: GLG Expert Contributor
A study reported in the March issue of Archives of Ophthalmology describes a new intravitreous drug delivery system for treating persistent retinal macular swelling. Using dexamethasone DDS and appropriate follow up, patients with this new system had significantly improved vision and and safety mea...
July 2, 2007
ANti VGEF THERAPIES ARE NOT JUST FOR MACULAR DEGENERATION
Analysis of: Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage | www.retinajournal.com
Author: GLG Expert Contributor
A study by Costa et al. reported in the prestigopis journal RETINA, of seven seven patients with macular SWELLING associated with ischemic retinal vein occlusion treated with intravitreal bevacizumab showed promising short-term results. Patients received two injections of bevacizumab (Avastin)...
July 2, 2007
PHAKIC IOLS ARE NOT DEAD
Analysis of: Artisan Phakic Intraocular Lens Safe, Effective After 10 Years | www.ophsource.org
Author: GLG Expert Contributor
Tahzib et al. conducted a 10-year retrospective follow-up study of the Artisan phakic intraocular lens (PIOL) for the correction of moderate to high nearsigtedness and concluded the device is both stable and predictable, but only when strict inclusion criteria are used. Over 90% of patients achieved...

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Next91 to 100 of 158

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T13:45:22.747